Switch to dolutegravir and unboosted atazanavir in HIV-1 infected patients with undetectable viral load and long exposure to antiretroviral therapy-Reference-Cited by-同舟云学术

Switch to dolutegravir and unboosted atazanavir in HIV-1 infected patients with undetectable viral load and long exposure to antiretroviral therapy

Published:2019-06-01 Issue:7 Volume:33 Page:1256-1260
ISSN:0269-9370
Container-title:AIDS
language:en
Short-container-title:

Author:

Castagna Antonella,Rusconi Stefano,Gulminetti Roberto,Bonora Stefano,Mazzola Giovanni,Quiros-Roldan Maria E.,De Socio Giuseppe V.,Ladisa Nicoletta,Carosella Sinibaldo,Cattelan Annamaria,Di Giambenedetto Simona,Mena Maurizio,Poli Andrea,Galli Laura,Riva Agostino

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Infectious Diseases,Immunology,Immunology and Allergy

Reference21 articles.

1. Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, noninferiority SWORD-1 and SWORD-2 studies;Llibre;Lancet,2018

2. Switch to dolutegravir plus rilpivirine dual therapy in cART-experienced subjects: an observational cohort;Capetti;PLoS One,2016

3. Efficacy and safety of dolutegravir and rilpivirine dual therapy as a simplification strategy: a cohort study;Gantner;HIV Med,2017

4. Virological control and metabolic improvement in HIV infected, virologically suppressed patients switching to lamivudine/dolutegravir dual therapy;Borghetti;J Antimicrob Chemother,2016

5. Lamivudine/dolutegravir dual therapy in HIV-infected, virologically suppressed patients;Maggiolo;BMC Infect Dis,2017

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prevalence of Emergent Dolutegravir Resistance Mutations in People Living with HIV: A Rapid Scoping Review;Viruses;2024-03-04

2. Different effects of the companion antiretroviral drugs on dolutegravir trough concentrations;AIDS;2024-01-15

3. Risk of Emergent Dolutegravir Resistance Mutations In People Living With HIV: A Rapid Scoping Review;2024-01-07

4. Real-world discontinuations due to neuropsychiatric symptoms in people living with HIV treated with second-generation integrase inhibitors: a systematic review;Expert Review of Anti-infective Therapy;2023-04-20

5. Cardiovascular risks associated with protease inhibitors for the treatment of HIV;Expert Opinion on Drug Safety;2021-07-26